The inhibition of HER2 with trastuzumab on one hand leads to a significant reduction of primary tumor growth as well as a significant reduction of metastases and to significant changes in the expression levels of HER2 and CXCR4 in the primary tumor. Here, ERBB2 is linked to neoplasm.